StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals GTN rebate accruals — Credits and payments made by Year

GTN rebate accruals — Credits and payments made ($M) ($M)

Vertex Pharmaceuticals GTN rebate accruals — Credits and payments made: -$3,520M in FY2025, down 5.5% from a year earlier.

Latest, FY2025
-3,520
Period ended Dec 31, 2025
Change on a year earlier
-5.5%
-3,725 in FY2024
History
13 years
Since FY2013
Sources
11
Documents cited below

Where the FY2025 figure comes from

“|| Credits/payments made | (3,519.5)”

Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-K MD&A (Critical Accounting Policies — Gross-to-Net Rebate Rollforward).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGTN rebate accruals — Credits and payments made ($M) ($M)Year on yearSource
FY2025Dec 31, 2025-3,520-5.5%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2024Dec 31, 2024-3,725+21.6%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2023Dec 31, 2023-3,065+21.9%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2022Dec 31, 2022-2,514+23.5%Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗
FY2021Dec 31, 2021-2,036+77.8%Form 10-K (vrtx-20231231.htm, filed 2024-02-15) ↗
FY2020Dec 31, 2020-1,145+143.6%Form 10-K (vrtx-20221231.htm, filed 2023-02-10) ↗
FY2019Dec 31, 2019-470+104.8%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
FY2018Dec 31, 2018-229+66.5%Form 10-K (vrtx-20201231.htm, filed 2021-02-11) ↗
FY2017Dec 31, 2017-138+41.9%Form 10-K (a201910k-main.htm, filed 2020-02-13) ↗
FY2016Dec 31, 2016-97.1+215.3%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2015Dec 31, 2015-30.8-59.0%Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗
FY2014Dec 31, 2014-75.2-63.2%Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗
FY2013Dec 31, 2013-204–Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals GTN rebate accruals — Credits and payments made ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/gtn-credits-paid

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.